<sup>68</sup>Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of <sup>68</sup>Ga-FAPI-46 with <sup>18</sup>F-FDG in 13 patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42171731.
- Also identified by DOI 10.1007/s00259-026-07916-0 and PMC identifier 13421285.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Oncological treatment in a substantial portion of patients with cancer of unknown primary (CUP) remains challenging due to limitations of conventional imaging and positron emission tomography/computed tomography with <sup>18</sup>Fluor-fluorodeoxyglucose (<sup>18</sup>F-FDG-PET/CT). In head and neck-like CUP (HNCUP), several studies found significantly higher tracer-uptake and detection rates of primary tumors in <sup>68</sup>Gallium-labeled fibroblast activation protein inhibitor-PET/CT (<sup>68</sup>Ga-FAPI-PET/CT). Here, we address a gap in CUP literature by retrospectively evaluating the diagnostic accuracy of both tracer in a head-to-head comparison of patients with single-site and oligometastatic extra-cervical CUP. 13 patients with extra-cervical CUP underwent both <sup>18</sup>F-FDG- and <sup>68</sup>Ga-FAPI-PET/CT. Suspicious PET-positive lesions were delineated using the volume of interest-technique (50%-isocontour) followed by analysis of maximum and mean standardized uptake values (SUVmax/mean), target-to-background ratios (TBRmax/mean) and tumor-to-tissue ratios (TTRmax/mean). Descriptive analysis was performed and log-transformation was applied to meet model assumptions and stabilize variance. The difference between log-transformed <sup>68</sup>Ga-FAPI- and <sup>18</sup>F-FDG-uptake values was used as outcome variables. 21 metastases of 3 patients with single-site and 6 patients with oligometastasized CUP were analyzed. 4 patients with previously extirpated metastases showed no uptake. No increased detection rate of primary tumors could be observed by either tracer. Differences of TBRmax in all metastatic sites and of TTRmax in organ metastases were significant. <sup>68</sup>Ga-FAPI-PET/CT lead to detection of 5/21 additional metastases which were not clearly distinguishable in <sup>18</sup>F-FDG-PET/CT. Due to higher tissue contrast in organs, our findings suggest that <sup>68</sup>Ga-FAPI-PET/CT appears favourable compared to <sup>18</sup>F-FDG-PET/CT particularly in patients with suspected distant metastases other than lymph nodes.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Fluorodeoxyglucose F18
- Radiopharmaceuticals
- Neoplasms, Unknown Primary
- Fibroblast Activation Protein Alpha